Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the H.C. Wainwright Annual Global Investment Conference scheduled for May 24, 2022. The company specializes in bioengineering transplantable organs to address organ shortages. Interested parties can access the presentation via webcast starting at 7 am ET on the conference date. Miromatrix focuses on developing human livers and kidneys using proprietary technology to improve patient lives.
Positive
- Participation in a notable investment conference can enhance company visibility.
- Focus on bioengineering transplantable organs addresses a critical healthcare need.
Negative
- None.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was -1.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., May 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.
Miromatrix Medical’s management is scheduled to present at the H.C. Wainwright Annual Global Investment Conference. Interested parties can access the webcast beginning Tuesday, May 24, 2022, at 7am ET, here.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.